|
|
Vaccine Detail
|
Unconjugated Myeloma Ig Id Vaccine |
| Vaccine Information |
- Vaccine Name: Unconjugated Myeloma Ig Id Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007126
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: A-myeloma proteins were of BALB/c-2 or BALB/c origin (produced by plasmacytomas MOPC-315, MOPC-460, Adj. PC-22A (Sirisinha and Eisen, 1971).
- Description: This is for Myeloma Cancer (NCT00001561). A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth (NCI04) (Sirisinha and Eisen, 1971; NCIT_C2822).
|
| Host Response |
|
|
| References |
NCIT_C2822: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822]
NCT00001561: [https://clinicaltrials.gov/ct2/show/NCT00001561]
Sirisinha and Eisen, 1971: Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proceedings of the National Academy of Sciences of the United States of America. 1971; 68(12); 3130-3135. [PubMed: 4108872].
|
|
